Abbott partners with Weight Watchers to improve diabetes management

Abbott Laboratories and Weight Watchers are partnering to help people with diabetes better understand their disease and manage their weight.

To accomplish this, New York-based Weight Watchers will integrate its diabetes-friendly weight management program with Abbott’s FreeStyle Libre product portfolio.

The goal is for the combination to create a seamless mobile experience that will empower people living with diabetes with the information and knowledge to make healthy adjustments to their diet, improve blood sugar levels, and ultimately better control their health.

“We strive to put our customers at the heart of everything we do, and that includes forming strategic partnerships with key industry leaders, like Weight Watchers, to deliver new services and offerings that can greatly improve the quality of life for people living with diabetes,” said Jared Watkin, senior vice president of Abbott’s diabetes care business. “By combining our world-leading FreeStyle Libre blood glucose monitoring technology with the number one weight loss program recommended by Weight Watchers doctors, people with diabetes, especially those with type 2 diabetes and below intensively managed by doctors, can get the information they need to take control of their health.”

Abbott’s Freestyle Libre products are among the most popular products on the diabetes management market. The company was able to change the diabetes management paradigm when it won FDA approval for the Freestyle Libre Flash blood glucose monitoring system in 2017.

The product was popular because it eliminated routine finger pricks, which until then had been the norm in blood sugar testing for over 40 years.

Abbott continued to replicate its success around the Freestyle when it gained clearance for the next generation of the device in 2020. The Freestyle Libre 2 iCGM was a step forward as it could be used in adults and children over four years for 14 days.

In early June, Abbott said it had obtained FDA clearance for the Freestyle Libre 3 system. Abbott said the Libre 3 sensor is the smallest and thinnest on the market at the size of a stacked two US pennies.

The device won the bronze award at the 2022 Medical Design Excellence Awards in the category of digital health products and mobile medical applications.

During the company’s most recent earnings conference call, Robert Ford, Chairman and CEO of Abbott, spoke about the company’s success with the FreeStyle Libre wallet.

“In diabetes care, sales of FreeStyle Libre grew more than 25% on an organic basis in the quarter, and our user base now exceeds four million users worldwide,” Ford said. , according to a Motley Fool. transcript of the call.

About John Tuttle

Check Also

New FDA draft guidelines aim to protect children participating in clinical trials

SILVER SPRING, MD., September 23, 2022 /PRNewswire/ — Today, the United States Food and Drug …